In particular, with regard to the common tyrosine-kinase inhibitors (TKIs), such as gefitinib, erlotinib, or afatinib, their role in cancer has been already shown, especially in NSCLC patients, which show mutations activating the epidermal growth factor receptor (EGFR) [138,240,241]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.